Clinical profile and response to treatment of patients with psoriasis seen via teledermatology during the COVID-19 pandemic in the Philippines

To the Editor: Psoriasis is a chronic disease that requires long-term follow-up. The COVID-19 pandemic has prompted us to increase the use of teledermatology (TD) to care for our patients with psoriasis. We conducted a descriptive cross-sectional study of our patients with psoriasis seen via TD during the pandemic, describing their demographic and clinical profile and evaluating their response to treatment.

We reviewed 424 charts of patients with psoriasis seen via TD who had new-onset psoriasis flareup and who had a follow-up at 1 month. The study

Table I. Demographic and clinical profile ofpatients with psoriasis seen via teledermatology inRizal Medical Center

Characteristics	Mean (SD) or frequency (%) <i>n</i> = 424		
Age, y	34 (SD, 13)		
0-18	34 (8%)		
19-30	144 (34%)		
31-40	118 (28%)		
41-50	69 (16%)		
51-60	39 (9%)		
>60	20 (5%)		
Sex			
Male	159 (38%)		
Female	265 (63%)		
Type of patient			
New	221 (52%)		
Returning	203 (48%)		
Method of diagnosis			
Clinical	399 (94%)		
Histologic	25 (6%)		
Disease severity*			
Mild	171 (40%)		
Moderate	216 (51%)		
Severe	27 (9%)		
Subtype by morphology			
Plaque	367 (87%)		
Guttate	31 (7%)		
Erythrodermic	17 (4%)		
Pustular	9 (2%)		
	Continued		

© 2022 by the American Academy of Dermatology, Inc. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Table I. Cont'd

AntitutisticsRequire (%) $n = 424$ Subtype by locationScalp237 (56%)Face27 (6%)Palmoplantar7 (2%)Inverse7 (2%)Inverse7 (2%)Genital3 (1%)Nail findingPresentPresent209 (49%)Absent215 (51%)Psoriatic arthritisPresentPresent77 (18%)Absent347 (82%)With cardiovascular69 (16%)comorbidity4 (6%)Diabetes/prediabetes14 (3%)Dyslipidemia1 (0.2%)With noncardiovascular2 (0.5%)comorbidity1 (0.2%)Liver disease1 (0.2%)With noncardiovascular2 (0.5%)comorbidity10.2%)Liver disease1 (0.2%)With noncardiovascular2 (0.5%)comorbidity10.2%)Liver disease1 (0.2%)Kidney disease1 (0.2%)None127Non-lifestyle factor100Mental stress195 (46%)Changes in weather56 (13%)Discontinuation or lack of44 (10%)medication1Infection43 (10%)Trauma2 (0.5%)Lifestyle factor2Poor sleep23 (5%)Overeating6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment10.2%)Monotherapy191 (45%)Topical corticoster	Characteristics	Mean (SD) or frequency $(9/2) = 42/2$
Subtype by location Scalp 237 (56%) Face 27 (6%) Palmoplantar 7 (2%) Inverse 7 (2%) Genital 3 (1%) Nail finding Present 209 (49%) Absent 215 (51%) Psoriatic arthritis Present 77 (18%) Absent 347 (82%) With cardiovascular 69 (16%) comorbidity Hypertension 30 (7%) Overweight/obesity 24 (6%) Diabetes/prediabetes 14 (3%) Dyslipidemia 1 (0.2%) With noncardiovascular 2 (0.5%) comorbidity Liver disease 1 (0.2%) Kidney disease 1 (0.2%) Kidney disease 1 (0.2%) Kidney disease 1 (0.2%) Reported trigger [†] None 127 Non-lifestyle factor Mental stress 195 (46%) Changes in weather 56 (13%) Discontinuation or lack of 44 (10%) medication Infection 43 (10%) Trauma 2 (0.5%) Lifestyle factor Poor sleep 23 (5%) Overeating 6 (1%) Alcohol intake 4 (1%) No exercise/sedentary lifestyle 1 (0.2%) Treatment Monotherapy 191 (45%) Topical corticosteroid 131 (31%) Topical corticosteroid + 108 (25%) vitamin D analog Topical + methotrexate 118 (28%) Topical + secukinumab 4 (0.9%) Topical + secukinumab 4 (0.9%)		n = 424
Scalp257 (36%)Face27 (6%)Palmoplantar7 (2%)Inverse7 (2%)Genital3 (1%)Nail finding215 (51%)Present209 (49%)Absent215 (51%)Psoriatic arthritisPresentPresent77 (18%)Absent347 (82%)With cardiovascular69 (16%)comorbidity46 (6%)Diabetes/prediabetes14 (3%)Dyslipidemia1 (0.2%)With noncardiovascular2 (0.5%)comorbidity10.2%)Kidney disease1 (0.2%)Kidney disease1 (0.2%)Reported trigger†10.2%)None127Non-lifestyle factor127Mental stress195 (46%)Changes in weather56 (13%)Discontinuation or lack of44 (10%)medication1Infection43 (10%)Trauma2 (0.5%)Lifestyle factorPoor sleepPoor sleep23 (5%)Overeating6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)TreatmentMonotherapyMonotherapy191 (45%)Topical corticosteroid131 (31%)Topical corticosteroid +108 (25%)Vitamin D analog4 (0.9%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical + secukinumab4 (0.9%)Topical + secukinumab4 (0.9%) <td></td> <td>227 (5604)</td>		227 (5604)
Pale27 (0%)Palmoplantar7 (2%)Inverse7 (2%)Genital3 (1%)Nail finding \mathbb{P} Present209 (49%)Absent215 (51%)Psoriatic arthritis \mathbb{P} Present77 (18%)Absent347 (82%)With cardiovascular69 (16%)comorbidity \mathbb{P} Hypertension30 (7%)Overweight/obesity24 (6%)Diabetes/prediabetes14 (3%)Dyslipidemia1 (0.2%)With noncardiovascular2 (0.5%)comorbidity \mathbb{P} Liver disease1 (0.2%)Kidney disease1 (0.2%)Reported trigger† \mathbb{P} None127None127None127None127None127None127None127None127None127None127None127None127None127None127None127None127None127None127None127Non-lifestyle factor10Poor sleep23 (5%)Overeating6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment10Monotherapy191 (45%)Topical vitamin D analog4 (1%)Nethotrexate<	Scalp Esco	237 (30%)
Paintoplantal7 (2%) (2%) GenitalNail finding7 (2%) (3 (1%)Present209 (49%) AbsentAbsent215 (51%)Prosent arthritis77 (18%) AbsentPresent77 (18%) (4%)Absent347 (82%)With cardiovascular69 (16%) comorbidityHypertension30 (7%) Overweight/obesityOverweight/obesity24 (6%) Diabetes/prediabetesDiabetes/prediabetes14 (3%) DyslipidemiaDyslipidemia1 (0.2%)With noncardiovascular2 (0.5%) comorbidityLiver disease1 (0.2%)Kidney disease1 (0.2%)Reported trigger [†] NoneNone127None-lifestyle factor44 (10%) medicationInfection43 (10%) Changes in weatherJoiscontinuation or lack of Mental stress44 (10%) medicationInfection43 (10%) ChangesTrauma2 (0.5%)Lifestyle factor90 (1%)Poor sleep23 (5%) OvereatingOvereating6 (1%) Alcohol intakeMonotherapy191 (45%) Topical corticosteroidTopical corticosteroid131 (31%) Topical corticosteroidTopical + methotrexate118 (28%) Topical + methotrexateMonotherapy233 (55%) Topical + secukinumabA (0.9%)Topical + secukinumabA (0.9%)100%)	Face	27 (0%)
Inverse7 (2%)Genital3 (1%)Nail finding7Present209 (49%)Absent215 (51%)Psoriatic arthritis7Present77 (18%)Absent347 (82%)With cardiovascular69 (16%)comorbidity4Hypertension30 (7%)Overweight/obesity24 (6%)Diabetes/prediabetes14 (3%)Dyslipidemia1 (0.2%)With noncardiovascular2 (0.5%)comorbidity1Liver disease1 (0.2%)Kidney disease1 (0.2%)Reported trigger [†] 10.2%)None127Non-lifestyle factor44 (10%)medication1Infection43 (10%)Trauma2 (0.5%)Lifestyle factor7Poor sleep23 (5%)Overeating6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment9 (2%)Secukinumab4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical + secukinumab4 (0.9%)Topical + secukinumab4 (0.9%)Topical + secukinumab4 (0.9%)Topical + secukinumab4 (0.9%)	Faimopiantai	7 (2%)
Gentral3 (1%)Nail findingPresent209 (49%)Absent215 (51%)Psoriatic arthritisPresent77 (18%)Absent347 (82%)With cardiovascular69 (16%)comorbidityHypertension30 (7%)Overweight/obesity24 (6%)Diabetes/prediabetes14 (3%)Dyslipidemia1 (0.2%)With noncardiovascular2 (0.5%)comorbidity1Liver disease1 (0.2%)Kidney disease1 (0.2%)Reported trigger [†] 10.2%)None127None-lifestyle factor4 (10%)Mental stress195 (46%)Changes in weather56 (13%)Discontinuation or lack of44 (10%)medication1Infection43 (10%)Trauma2 (0.5%)Lifestyle factor7Poor sleep23 (5%)Overeating6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment4 (0.9%)Monotherapy191 (45%)Topical corticosteroid131 (31%)Topical corticosteroid131 (31%)Topical vitamin D analog4 (0.9%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical + secukinumab4 (0.9%)Topical + secukinumab4 (0.9%)Topical + secukinumab4 (0.9%)	Conital	7 (Z%) 2 (104)
Name209 (49%) AbsentPresent215 (51%)Psoriatic arthritis77 (18%) AbsentPresent77 (18%) AbsentAbsent347 (82%)With cardiovascular69 (16%) comorbidityHypertension30 (7%) Overweight/obesityDiabetes/prediabetes14 (3%) DyslipidemiaDyslipidemia1 (0.2%)With noncardiovascular2 (0.5%) comorbidityLiver disease1 (0.2%)Kidney disease1 (0.2%)Reported trigger†7None127None-lifestyle factor127Mental stress195 (46%) Changes in weatherChanges in weather56 (13%) Discontinuation or lack ofHa (10%) medication2 (0.5%)Lifestyle factor2 (0.5%)Poor sleep23 (5%) OvereatingOvereating6 (1%) Alcohol intakeMonotherapy191 (45%) Topical corticosteroidTopical corticosteroid131 (31%) Topical corticosteroidMethotrexate9 (2%) SecukinumabSecukinumab4 (0.9%) CyclosporineCombination therapy233 (55%) Topical + methotrexateMoncial + secukinumab4 (0.9%) CyclosporineTopical + secukinumab <td< td=""><td>Genildi Nail finding</td><td>5 (1%)</td></td<>	Genildi Nail finding	5 (1%)
Present205 (49%)Absent215 (51%)Psoriatic arthritisPresentPresent77 (18%)Absent347 (82%)With cardiovascular69 (16%)comorbidity24 (6%)Diabetes/prediabetes14 (3%)Dyslipidemia1 (0.2%)With noncardiovascular2 (0.5%)comorbidity2Liver disease1 (0.2%)Kidney disease1 (0.2%)Reported trigger [†] 10.2%)None127Non-lifestyle factor127Mental stress195 (46%)Changes in weather56 (13%)Discontinuation or lack of44 (10%)medication23 (5%)Overeating6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment131 (31%)Topical corticosteroid131 (31%)Topical vitamin D analog46 (11%)Methotrexate9 (2%)Secukinumab4 (0.9%)Cyclosporine1 (0.2%)Topical + methotrexate118 (28%)Topical + secukinumab4 (0.9%)Vitamin D analog4 (0.9%)Topical + secukinumab4 (0.9%)	Brocont	200 (40%)
Psoriatic arthritis Present 77 (18%) Absent 347 (82%) With cardiovascular 69 (16%) comorbidity Hypertension 30 (7%) Overweight/obesity 24 (6%) Diabetes/prediabetes 14 (3%) Dyslipidemia 1 (0.2%) With noncardiovascular 2 (0.5%) comorbidity Liver disease 1 (0.2%) Kidney disease 1 (0.2%) Kidney disease 1 (0.2%) Reported trigger [†] None 127 Non-lifestyle factor Mental stress 195 (46%) Changes in weather 56 (13%) Discontinuation or lack of 44 (10%) medication Infection 43 (10%) Trauma 2 (0.5%) Lifestyle factor Poor sleep 23 (5%) Overeating 6 (1%) Smoking 6 (1%) Alcohol intake 4 (1%) No exercise/sedentary lifestyle 1 (0.2%) Treatment Monotherapy 191 (45%) Topical corticosteroid 131 (31%) Topical vitamin D analog 46 (11%) Methotrexate 9 (2%) Secukinumab 4 (0.9%) Cyclosporine 1 (0.2%) Topical + methotrexate 118 (28%) Topical + secukinumab 4 (0.9%) Topical + secukinumab 4 (0.9%) Topical + secukinumab 4 (0.9%)	Abcont	209 (49%)
Present77 (18%) AbsentAbsent347 (82%)With cardiovascular69 (16%) comorbidityHypertension30 (7%)Overweight/obesity24 (6%) Diabetes/prediabetesDiabetes/prediabetes14 (3%) DyslipidemiaDyslipidemia1 (0.2%)With noncardiovascular2 (0.5%) comorbidityLiver disease1 (0.2%)Kidney disease1 (0.2%)Reported trigger†NoneNone127None-lifestyle factor44 (10%) medicationInfection43 (10%) TraumaInfection43 (10%) TraumaZ (0.5%)Cifestyle factorPoor sleep23 (5%) OvereatingOvereating6 (1%) SmokingAlcohol intake4 (1%) No exercise/sedentary lifestyleNontherapy191 (45%) Topical corticosteroidTopical vitamin D analog46 (11%) MethotrexateMonotherapy233 (55%) Topical corticosteroid +118 (28%) Topical corticosteroid +118 (28%) Topical corticosteroid +118 (28%) Topical corticosteroid +118 (28%) Topical + secukinumab4 (0.9%) Topical + secukinumab4 (0.9%) Topical + secukinumab4 (0.9%) Topical + secukinumab4 (0.9%) Topical + secukinumab	Absent Description arthritic	213 (31%)
Absent $347 (82\%)$ With cardiovascular $69 (16\%)$ comorbidityHypertensionHypertension $30 (7\%)$ Overweight/obesity $24 (6\%)$ Diabetes/prediabetes $14 (3\%)$ Dyslipidemia $1 (0.2\%)$ With noncardiovascular $2 (0.5\%)$ comorbidity $2000000000000000000000000000000000000$	Procont	77 (19%)
Absent347 (82%)With cardiovascular69 (16%)comorbidity90 (16%)Pypertension30 (7%)Overweight/obesity24 (6%)Diabetes/prediabetes14 (3%)Dyslipidemia1 (0.2%)With noncardiovascular2 (0.5%)comorbidity2000Liver disease1 (0.2%)Kidney disease1 (0.2%)Reported trigger [†] 1000None127Non-lifestyle factor1000Mental stress195 (46%)Changes in weather56 (13%)Discontinuation or lack of44 (10%)medication1000Infection43 (10%)Trauma2 (0.5%)Lifestyle factor23 (5%)Overeating6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment11 (11%)Monotherapy191 (45%)Topical corticosteroid131 (31%)Topical vitamin D analog46 (11%)Methotrexate9 (2%)Secukinumab4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical - methotrexate118 (28%)Topical - methotrexate118 (28%)Topical + secukinumab4 (0.9%)Vitamin D analog70pical + secukinumabMore corticosteroid + 108 (25%)10000Topical + secukinumab4 (0.9%)Topical + secukinumab4 (0.9%)Topical + secukinumab4 (0.9%) </td <td>Abcont</td> <td>77 (10%) 247 (0204)</td>	Abcont	77 (10%) 247 (0204)
With Caldovactual0.9 (10%)comorbidityHypertension30 (7%)Overweight/obesity24 (6%)Diabetes/prediabetes14 (3%)Dyslipidemia1 (0.2%)With noncardiovascular2 (0.5%)comorbidity2Liver disease1 (0.2%)Kidney disease1 (0.2%)Reported trigger [†] 10.2%)None127Non-lifestyle factor195 (46%)Changes in weather56 (13%)Discontinuation or lack of44 (10%)medication1Infection43 (10%)Trauma2 (0.5%)Overeating6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment11 (31%)Monotherapy191 (45%)Topical corticosteroid131 (31%)Topical vitamin D analog46 (11%)Methotrexate9 (2%)Secukinumab4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical + secukinumab4 (0.9%)Topical + secukinumab4 (0.9%)	With cardiovascular	547 (62%) 69 (16%)
Hypertension30 (7%)Overweight/obesity24 (6%)Diabetes/prediabetes14 (3%)Dyslipidemia1 (0.2%)With noncardiovascular2 (0.5%)comorbidity1Liver disease1 (0.2%)Kidney disease1 (0.2%)Reported trigger [†] NoneNon127Non-lifestyle factor44 (10%)medication116Infection43 (10%)Trauma2 (0.5%)Lifestyle factor90 sleepPoor sleep23 (5%)Overeating6 (1%)Smoking6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment191 (45%)Topical corticosteroid131 (31%)Topical corticosteroid131 (31%)Topical corticosteroid +108 (25%)Vitamin D analog4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical + secukinumab4 (0.9%)Vitamin D analogTopical + secukinumabVitamin D analog100 (25%)Vitamin D analog100 (25%)Vitamin D analog100 (25%)Topical + secukinumab4 (0.9%)Topical + secukinumab4 (0.9%) </td <td>comorbidity</td> <td>09 (10%)</td>	comorbidity	09 (10%)
hypertension30 (7%)Overweight/obesity24 (6%)Diabetes/prediabetes14 (3%)Dyslipidemia1 (0.2%)With noncardiovascular2 (0.5%)comorbidity1Liver disease1 (0.2%)Kidney disease1 (0.2%)Reported trigger [†] NoneNon-lifestyle factor127Mon-lifestyle factor44 (10%)medication116Infection43 (10%)Trauma2 (0.5%)Lifestyle factor90 sleepPoor sleep23 (5%)Overeating6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment191 (45%)Topical corticosteroid131 (31%)Topical corticosteroid131 (31%)Topical corticosteroid +108 (25%)Vitamin D analog4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical + secukinumab4 (0.9%)Topical + secukinumab4 (0.9%) <td>Hypertension</td> <td>20 (704)</td>	Hypertension	20 (704)
Overweight/objestly24 (0%)Diabetes/prediabetes14 (3%)Dyslipidemia1 (0.2%)With noncardiovascular2 (0.5%)comorbidity1Liver disease1 (0.2%)Kidney disease1 (0.2%)Reported trigger [†] 10.2%)None127None127None127None127None127None127None127None127None20(0.2%)Changes in weather56 (13%)Discontinuation or lack of44 (10%)medication1Infection43 (10%)Trauma2 (0.5%)Lifestyle factor20(0.5%)Poor sleep23 (5%)Overeating6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment131 (31%)Topical corticosteroid131 (31%)Topical vitamin D analog46 (11%)Methotrexate9 (2%)Secukinumab4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical + secukinumab4 (0.9%)Vytamin D analog70pical + secukinumabVytamin D analog70pical + secukinumabVytamin D analog10,09%)Topical + secukinumab4 (0.9%)Topical + secukinumab4 (0.9%)Topical + secukinumab4 (0.9%) <tr <td="">Nopi</tr>	Overweight / chosity	50 (7%) 24 (6%)
Diabetes14 (3%)Dyslipidemia1 (0.2%)With noncardiovascular2 (0.5%)comorbidity1Liver disease1 (0.2%)Kidney disease1 (0.2%)Reported trigger [†] 127None127Nonlifestyle factor127Mental stress195 (46%)Changes in weather56 (13%)Discontinuation or lack of44 (10%)medication110%)Infection43 (10%)Trauma2 (0.5%)Lifestyle factor20 (5%)Poor sleep23 (5%)Overeating6 (1%)Smoking6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment131 (31%)Topical corticosteroid131 (31%)Topical vitamin D analog46 (11%)Methotrexate9 (2%)Secukinumab4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical + secukinumab4 (0.9%)Vitamin D analog70pical + secukinumabVoical + cyclosporine3 (0.7%)	Diabatos/prodiabatos	24 (0%)
Dysipidemia1 (0.2%)With noncardiovascular2 (0.5%)comorbidity1Liver disease1 (0.2%)Kidney disease1 (0.2%)Reported trigger†1None127Non-lifestyle factor127Mental stress195 (46%)Changes in weather56 (13%)Discontinuation or lack of44 (10%)medication1Infection43 (10%)Trauma2 (0.5%)Lifestyle factor23 (5%)Poor sleep23 (5%)Overeating6 (1%)Smoking6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment131 (31%)Topical corticosteroid131 (31%)Topical vitamin D analog46 (11%)Methotrexate9 (2%)Secukinumab4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical corticosteroid +118 (28%)Topical + secukinumab4 (0.9%)Cyclosporine1 (0.2%)	Diabetes/prediabetes	14 (5%)
With honcarlovascular $2 (0.3\%)$ comorbidityLiver disease1 (0.2%)Kidney disease1 (0.2%)Reported trigger [†] 1000000000000000000000000000000000000	With papeardiovascular	T (0.2%)
Liver disease1 (0.2%)Kidney disease1 (0.2%)Reported trigger† 10.2% None127Non-lifestyle factor 195 (46%)Changes in weather56 (13%)Discontinuation or lack of44 (10%)medication 116 Infection43 (10%)Trauma2 (0.5%)Lifestyle factor 0000 Poor sleep23 (5%)Overeating6 (1%)Smoking6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment 10000 Monotherapy191 (45%)Topical corticosteroid131 (31%)Topical vitamin D analog46 (11%)Methotrexate9 (2%)Secukinumab4 (0.9%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical - tropical - therapy108 (25%)vitamin D analog4 (0.9%)Topical + secukinumab4 (0.9%)Topical + secukinumab4 (0.9%)Topical + cyclosporine3 (0.7%)	with honcardiovascular	2 (0.5%)
Liver disease1 (0.2%)Kidney disease1 (0.2%)Reported trigger†127None127Non-lifestyle factor195 (46%)Changes in weather56 (13%)Discontinuation or lack of44 (10%)medication11Infection43 (10%)Trauma2 (0.5%)Lifestyle factor23 (5%)Poor sleep23 (5%)Overeating6 (1%)Smoking6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment191 (45%)Topical corticosteroid131 (31%)Topical vitamin D analog46 (11%)Methotrexate9 (2%)Secukinumab4 (0.9%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical - secukinumab4 (0.9%)Topical + secukinumab4 (0.9%)Topical + secukinumab4 (0.9%)Topical + cyclosporine3 (0.7%)		1 (0.20%)
Nume1 (0.2%)Reported trigger [†] 127None127Non-lifestyle factor195 (46%)Changes in weather56 (13%)Discontinuation or lack of44 (10%)medication11Infection43 (10%)Trauma2 (0.5%)Lifestyle factor23 (5%)Poor sleep23 (5%)Overeating6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment191 (45%)Topical corticosteroid131 (31%)Topical vitamin D analog46 (11%)Methotrexate9 (2%)Secukinumab4 (0.9%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical - secukinumab4 (0.9%)Topical + secukinumab4 (0.9%)Topical + cyclosporine3 (0.7%)	Kidpov disease	1 (0.2%)
None127Non-lifestyle factor195 (46%)Mental stress195 (46%)Changes in weather56 (13%)Discontinuation or lack of44 (10%)medication1Infection43 (10%)Trauma2 (0.5%)Lifestyle factor23 (5%)Poor sleep23 (5%)Overeating6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment191 (45%)Topical corticosteroid131 (31%)Topical vitamin D analog46 (11%)Methotrexate9 (2%)Secukinumab4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical - methotrexate118 (28%)Topical - methotrexate118 (28%)Topical + secukinumab4 (0.9%)Topical + secukinumab4 (0.9%)Topical + cyclosporine3 (0.7%)	Rulley disease	1 (0.2%)
None127Non-lifestyle factor195 (46%)Changes in weather56 (13%)Discontinuation or lack of44 (10%)medication11Infection43 (10%)Trauma2 (0.5%)Lifestyle factor23 (5%)Poor sleep23 (5%)Overeating6 (1%)Smoking6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment191 (45%)Topical corticosteroid131 (31%)Topical vitamin D analog46 (11%)Methotrexate9 (2%)Secukinumab4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical - methotrexate118 (28%)Topical corticosteroid +108 (25%)vitamin D analog4 (0.9%)Topical + secukinumab4 (0.9%)Topical + secukinumab4 (0.9%)Topical + cyclosporine3 (0.7%)	Nono	127
Non-Intestyle factorMental stress195 (46%)Changes in weather56 (13%)Discontinuation or lack of44 (10%)medication1Infection43 (10%)Trauma2 (0.5%)Lifestyle factor23 (5%)Poor sleep23 (5%)Overeating6 (1%)Smoking6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment191 (45%)Topical corticosteroid131 (31%)Topical vitamin D analog46 (11%)Methotrexate9 (2%)Secukinumab4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical - methotrexate118 (28%)Topical corticosteroid +108 (25%)vitamin D analog4 (0.9%)Topical + secukinumab4 (0.9%)Topical + secukinumab4 (0.9%)Topical + cyclosporine3 (0.7%)	Non-lifestyle factor	127
Mental stress193 (40%)Changes in weather56 (13%)Discontinuation or lack of44 (10%)medication1Infection43 (10%)Trauma2 (0.5%)Lifestyle factor2 (0.5%)Poor sleep23 (5%)Overeating6 (1%)Smoking6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment191 (45%)Topical corticosteroid131 (31%)Topical vitamin D analog46 (11%)Methotrexate9 (2%)Secukinumab4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical corticosteroid +108 (25%)vitamin D analog4 (0.9%)Topical + secukinumab4 (0.9%)Topical + secukinumab4 (0.9%)Topical + cyclosporine3 (0.7%)	Montal stross	105 (46%)
Discontinuation or lack of medication44 (10%)Infection43 (10%)Trauma2 (0.5%)Lifestyle factor23 (5%)Poor sleep23 (5%)Overeating6 (1%)Smoking6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment191 (45%)Topical corticosteroid131 (31%)Topical vitamin D analog46 (11%)Methotrexate9 (2%)Secukinumab4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical corticosteroid +108 (25%)vitamin D analog4 (0.9%)Topical + secukinumab4 (0.9%)Topical + secukinumab4 (0.9%)Topical + cyclosporine3 (0.7%)	Changes in weather	56 (13%)
Discontinuation of fact of medication44 (10%) medicationInfection43 (10%)Trauma2 (0.5%)Lifestyle factor23 (5%)Poor sleep23 (5%)Overeating6 (1%)Smoking6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment191 (45%)Monotherapy191 (45%)Topical corticosteroid131 (31%)Topical vitamin D analog46 (11%)Methotrexate9 (2%)Secukinumab4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical corticosteroid +108 (25%)vitamin D analog4 (0.9%)Topical + secukinumab4 (0.9%)Topical + cyclosporine3 (0.7%)	Discontinuation or lack of	JU (10%)
Infection43 (10%)Trauma2 (0.5%)Lifestyle factor23 (5%)Poor sleep23 (5%)Overeating6 (1%)Smoking6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment191 (45%)Monotherapy191 (45%)Topical corticosteroid131 (31%)Topical vitamin D analog46 (11%)Methotrexate9 (2%)Secukinumab4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical corticosteroid +108 (25%)vitamin D analog4 (0.9%)Topical + secukinumab4 (0.9%)Topical + cyclosporine3 (0.7%)	medication	++ (1070)
Infection43 (10%)Trauma2 (0.5%)Lifestyle factor9000000000000000000000000000000000000	Infection	43 (10%)
Lifestyle factor Poor sleep 23 (5%) Overeating 6 (1%) Smoking 6 (1%) Alcohol intake 4 (1%) No exercise/sedentary lifestyle 1 (0.2%) Treatment Monotherapy 191 (45%) Topical corticosteroid 131 (31%) Topical vitamin D analog 46 (11%) Methotrexate 9 (2%) Secukinumab 4 (0.9%) Cyclosporine 1 (0.2%) Combination therapy 233 (55%) Topical + methotrexate 118 (28%) Topical - therapy 4 (0.9%) vitamin D analog Topical + secukinumab 4 (0.9%) Topical + secukinumab 4 (0.9%) Topical + cyclosporine 3 (0.7%)	Trauma	2 (0 5%)
Poor sleep23 (5%)Overeating6 (1%)Smoking6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment191 (45%)Monotherapy191 (45%)Topical corticosteroid131 (31%)Topical vitamin D analog46 (11%)Methotrexate9 (2%)Secukinumab4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical corticosteroid +108 (25%)vitamin D analog7opical + secukinumab4 (0.9%)7opical + secukinumab5 (0.9%)3 (0.7%)		2 (0.570)
Overeating6 (1%)Overeating6 (1%)Smoking6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment191 (45%)Monotherapy191 (45%)Topical corticosteroid131 (31%)Topical vitamin D analog46 (11%)Methotrexate9 (2%)Secukinumab4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical corticosteroid +108 (25%)vitamin D analog7opical + secukinumabTopical + secukinumab4 (0.9%)Topical + cyclosporine3 (0.7%)	Poor sleep	23 (5%)
SourceSourceSmoking6 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment191 (45%)Monotherapy191 (45%)Topical corticosteroid131 (31%)Topical vitamin D analog46 (11%)Methotrexate9 (2%)Secukinumab4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical corticosteroid +108 (25%)vitamin D analog7opical + secukinumabTopical + secukinumab4 (0.9%)Topical + cyclosporine3 (0.7%)	Overeating	6 (1%)
Alcohol intake4 (1%)Alcohol intake4 (1%)No exercise/sedentary lifestyle1 (0.2%)Treatment191 (45%)Topical corticosteroid131 (31%)Topical vitamin D analog46 (11%)Methotrexate9 (2%)Secukinumab4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical corticosteroid +108 (25%)vitamin D analog7opical + secukinumabAlcondy4 (0.9%)Topical + secukinumab4 (0.9%)Topical + cyclosporine3 (0.7%)	Smoking	6 (1%)
No exercise/sedentary lifestyle1 (0.2%)Treatment191 (45%)Monotherapy191 (45%)Topical corticosteroid131 (31%)Topical vitamin D analog46 (11%)Methotrexate9 (2%)Secukinumab4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical corticosteroid +108 (25%)vitamin D analog4 (0.9%)Topical + secukinumab4 (0.9%)Topical + cyclosporine3 (0.7%)	Alcohol intake	4 (1%)
Treatment191 (45%)Monotherapy191 (45%)Topical corticosteroid131 (31%)Topical vitamin D analog46 (11%)Methotrexate9 (2%)Secukinumab4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical corticosteroid +108 (25%)vitamin D analog7Topical + secukinumab4 (0.9%)Topical + cyclosporine3 (0.7%)	No exercise/sedentary lifestyle	1 (0.2%)
Monotherapy191 (45%)Topical corticosteroid131 (31%)Topical vitamin D analog46 (11%)Methotrexate9 (2%)Secukinumab4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical corticosteroid +108 (25%)vitamin D analog7opical + secukinumabTopical + secukinumab4 (0.9%)Topical + cyclosporine3 (0.7%)	Treatment	1 (0.270)
Topical corticosteroid131 (31%)Topical vitamin D analog46 (11%)Methotrexate9 (2%)Secukinumab4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical corticosteroid +108 (25%)vitamin D analog7Topical + secukinumab4 (0.9%)Topical + cyclosporine3 (0.7%)	Monotherapy	191 (45%)
Topical vitamin D analog46 (11%)Methotrexate9 (2%)Secukinumab4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical corticosteroid +108 (25%)vitamin D analog7opical + secukinumabTopical + cyclosporine3 (0.7%)	Topical corticosteroid	131 (31%)
Methotrexate9 (2%)Secukinumab4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical corticosteroid +108 (25%)vitamin D analog7opical + secukinumabTopical + cyclosporine3 (0.7%)	Topical vitamin D analog	46 (11%)
Secukinumab4 (0.9%)Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical corticosteroid +108 (25%)vitamin D analog7opical + secukinumabTopical + cyclosporine3 (0.7%)	Methotrexate	9 (2%)
Cyclosporine1 (0.2%)Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical corticosteroid +108 (25%)vitamin D analog70pical + secukinumabTopical + secukinumab4 (0.9%)Topical + cyclosporine3 (0.7%)	Secukinumab	4 (0.9%)
Combination therapy233 (55%)Topical + methotrexate118 (28%)Topical corticosteroid +108 (25%)vitamin D analog70pical + secukinumabTopical + secukinumab4 (0.9%)Topical + cyclosporine3 (0.7%)	Cyclosporine	1 (0.2%)
Topical + methotrexate118 (28%)Topical corticosteroid +108 (25%)vitamin D analog70pical + secukinumab4 (0.9%)3 (0.7%)		233 (55%)
Topical corticosteroid +108 (25%)vitamin D analogTopical + secukinumab4 (0.9%)Topical + cyclosporine3 (0.7%)	Topical + methotrexate	118 (28%)
vitamin D analog Topical + secukinumab 4 (0.9%) Topical + cyclosporine 3 (0.7%)	Topical corticosteroid +	108 (25%)
Topical + secukinumab 4 (0.9%) Topical + cyclosporine 3 (0.7%)	vitamin D analog	
Topical + cyclosporine $3 (0.7\%)$	Topical $+$ secukinumab	4 (0.9%)
	Topical $+$ cyclosporine	3 (0.7%)

*Assessed using psoriasis area severity index and dermatology life quality index.

[†]Each patient can have more than 1 reported trigger.

Disease severity	PASI Mean (SD)		DLQI Mean (SD)			
	Baseline	After 1 mo	% decrease	Baseline	After 1 mo	% decrease
Mild	6.42 (4.52)	5.17 (4.21)	19%	10.94 (7.31)	9.76 (6.94)	11%
Moderate	16.03 (8.37)	12.85 (7.39)	20%	16.59 (7.54)	14.41 (8.15)	13%
Severe	27.2 (12.33)	20.1 (12.13)	26%	18.83 (6.14)	15.51 (7.89)	18%

Table II. Psoriasis area severity index and dermatology life quality index at baseline and after 1 month of treatment

DLQI, Dermatology life quality index; PASI, psoriasis area severity index.

duration was from October 2020 to April 2021. Table I shows the demographic and clinical profile of the cohort. Treatment response was evaluated by comparing the psoriasis area severity index (PASI) and dermatology life quality index (DLQI) at the time of new-onset flareup and at follow-up at 1 month (Table II). Mean PASI and DLQI decreased from the baseline to follow-up. PASI and DLQI reduction was the highest for severe disease, 26% and 18%, respectively. Moderate psoriasis had a 20% and 13% reduction, respectively, whereas mild disease had a 19% and 11% reduction, respectively, in PASI and DLQI.

Our study provides real-world data on the use of TD to care for patients with psoriasis during the pandemic. It is noteworthy that our patients were younger than those of 2 registry-based studies, the study by Ng et al¹ before the pandemic and the study by Mahil et al² during the pandemic, which had a mean age of patient of 44 years (SD, 16 years) and 47.2 years (SD, 15.1 years), respectively. It is possible that younger patients are more adept at using technology than older patients and may explain the greater number of patients aged <40 years in our study. We recommend a study on TD utilization patterns and feedback to help older patients keep abreast of technology.

Forty-six percent of our patients reported mental stress as a trigger of the disease flareup. This may be attributed to the effects of the pandemic, which has restricted mobility, caused the loss of income, and has led to stress, anxiety, and depression.³ We encourage psychosocial support for these patients.

The reduction in PASI and DLQI in our patients across all severity groups suggests that TD is a useful alternative in caring for patients with psoriasis, especially in this pandemic. In our institution, we use hybrid TD because most of our patients do not have a reliable internet connection, which precludes good-quality video conferencing. Hybrid TD allows us to better assess the condition through photographs sent via the Facebook messenger (store-and-forward TD) combined with a telephonic call (real-time interactive TD) to review patients' clinical history and explain management. We use the Facebook messenger because it is accessible to most patients, including those from resource-poor regions. Similarly, Angeles et al⁴ reported that most dermatologists in the Philippines use hybrid TD, with the Facebook messenger as the second most commonly used platform.

Limitations of our study include the lack of a control group and long-term follow-up. To validate our findings, we recommend including a cohort of patients with psoriasis seen in-office as a control group and including long-term follow-up assessments in future studies.

- Patricia Anne Tinio, MD, Jacqueline Michelle Melendres, MD, Czarina P. Chavez, MD, Maicka Keirsten Agon, MD, Arbie Sofia Merilleno, MD, Rogelio Balagat, MD, Lily Lyralin Tumalad, MD, Alma Gay Concepcion Amado, MD, and Francisco Rivera, IV, MD
- From the Department of Dermatology, Rizal Medical Center, Pasig Boulevard, Pasig, Philippines.
- Funding sources: None.
- IRB approval status: The study protocol was approved by institutional review board of the Rizal Medical Center (protocol code: 2021-D=#021=RP.2.II).
- *Key words: COVID-19; medical dermatology; Philippines; psoriasis; teledermatology; telemedicine.*
- Correspondence to: Czarina P. Chavez, MD, Department of Dermatology, Rizal Medical Center, Pasig Blvd, Pasig, Metro Manila 1600, Philippines

E-mail: chaipineda@gmail.com

Conflicts of interest

Dr Tinio has received honoraria as a member of the advisory board and speaker from Novartis, Janssen/J&J, and Zuellig Lilly. Dr Chavez has received fees as a speaker from LeoPharma and Glenmark and a research grant paid to her institution as principal investigator from Glenmark. Dr Balagat has received fees as a speaker from Novartis. Dr Tumalad has received honoraria as a speaker from Novartis, LeoPharma, and J&J and research funds as principal investigator from Novartis. Drs Melendres, Agon, Merilleno, Amado, and Rivera have no conflicts of interest to declare.

REFERENCES

- Ng JNC, Guevara BEG, Guillano VP. Demographic and clinical profiles of adult Filipino patients with psoriasis in Davao City: a cross sectional study. *J Philipp Dermatological Soc.* 2018;27(1): 41-63.
- 2. Mahil SK, Yates M, Yiu ZZN, et al. Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a

global cross-sectional study. J Eur Acad Dermatol Venereol. 2021;35(10):e636-e640. https://doi.org/10.1111/jdv.17450

- Kuang Y, Shen M, Wang Q, et al. Association of outdoor activity restriction and income loss with patient-reported outcomes of psoriasis during the COVID-19 pandemic: a web-based survey. J Am Acad Dermatol. 2020;83(2):670-672. https://doi.org/10.1016/j.jaad.2020.05.018
- Angeles C, Chavez C, Lim H, Guevara B, Jamisola L. Impact of the COVID-19 pandemic on dermatology practice in the Philippines: a cross-sectional study. *Australas J Dermatol.* 2021;62(4):e594-e596. https://doi.org/10.1111/AJD.13714

https://doi.org/10.1016/j.jdin.2022.02.001